Dr. Brian O’Rourke, President and CEO of the Canadian Agency for Drugs and Technologies in Health (CADTH), is pleased to announce that Dr. Andreas Laupacis, MD, MSc, FRCPC, is the inaugural recipient of the Jill M. Sanders Award of Excellence in Health Technology Assessment (HTA).
“Dr. Laupacis is a nationally and internationally recognized leader in the science and application of HTA,” said Dr. O’Rourke. “He has made remarkable contributions to the uptake and use of evidence-based information in Canada, including improving HTA methodology, conducting substantive assessments, supporting the adoption of evidence-based policies, and inspiring the next generation of researchers.”
Dr. Laupacis was the first Chair of the Canadian Expert Drug Advisory Committee and is the former President and CEO of the Institute for Clinical Evaluative Sciences. He is currently Executive Director of the Li Ka Shing Knowledge Institute of St. Michael’s Hospital and a Professor at the Department of Medicine and Department of Health Policy, Management and Evaluation, University of Toronto. He is also a member of the Alberta Health Services Board and chairs its Quality and Safety Committee.
The Jill M. Sanders Award of Excellence in HTA was established by CADTH to celebrate Canadian leadership and excellence in HTA by recognizing individuals whose outstanding achievements have significantly advanced health technology assessment and related fields in Canada.
The Award is named in honour of Dr. Jill M. Sanders, President and CEO of CADTH from 1987 to 2010. Dr. Sanders led the transformation of CADTH from a small office into an agency with a significant and growing impact on the quality and sustainability of health care in Canada and improved health outcomes. She passed away in February following a six-month battle with cancer.
“It is a huge and humbling honour to receive an award named for Jill Sanders who had a real passion for HTA,” said Dr. Laupacis. “The award is a living monument to what she accomplished with CADTH.”